Lyons, CO, United States of America

Robert Kirk DeLisle

USPTO Granted Patents = 11 

Average Co-Inventor Count = 11.5

ph-index = 2

Forward Citations = 15(Granted Patents)


Location History:

  • Boulder, CO (US) (2013 - 2015)
  • Lyons, CO (US) (2014 - 2020)

Company Filing History:


Years Active: 2013-2020

Loading Chart...
11 patents (USPTO):

Title: The Innovative Contributions of Robert Kirk DeLisle

Introduction

Robert Kirk DeLisle is a prominent inventor based in Lyons, Colorado, known for his significant contributions to the field of pharmaceuticals. With a total of 11 patents to his name, DeLisle has made remarkable advancements in the development of compounds that target various medical conditions.

Latest Patents

His latest patents include the development of substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds, which serve as type III receptor tyrosine kinase inhibitors. These compounds are designed to be effective in treating fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain, and burns in mammals. The innovative nature of these compounds highlights DeLisle's commitment to addressing critical health issues through scientific research.

Career Highlights

DeLisle is currently employed at Array Biopharma Inc., where he continues to push the boundaries of pharmaceutical innovation. His work has not only contributed to the advancement of medical treatments but has also positioned him as a key figure in the industry.

Collaborations

Throughout his career, DeLisle has collaborated with notable colleagues, including Qian Zhao and Mark C Munson. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Robert Kirk DeLisle's contributions to the field of pharmaceuticals through his innovative patents and collaborations underscore his importance as an inventor. His work continues to pave the way for new treatments that can significantly improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…